CADY Study ICORG 08-01

Inclusion Criteria

1. HER-2 positive breast cancer by immunohistochemistry and/or fluorescence in-situ hybridisation.
2. Planned neoadjuvant and/or adjuvant treatment with chemotherapy and Trastuzumab either sequentially or in combination or single agent Trastuzumab.
3. 18 years of age or older.
4. Disease Stage I-III, whose treatment plan includes Trastuzumab either sequentially, in combination or as a single agent will be eligible for inclusion in the study.
5. As this is a non-interventional study, patients enrolled in therapeutic clinical trials will also be eligible for inclusion.
6. Treatment with curative intent.
7. ECOG Performance status 0, 1 or 2.
8. Adequate cardiac function, with MUGA or Echocardiograph \> 50%.
9. Written informed consent.

Exclusion Criteria:

1. Presence of a medical or psychiatric condition, which, in the opinion of the investigator, would potentially pose a risk to the patient by participating in this trial.
2. Evidence of metastatic disease.
3. Patients with uncontrolled hypertension (sustained systolic blood pressure \>180mmHg or diastolic blood pressure \>100mmHg), significant valvular disease (aortic or mitral regurgitation of 3 or 4+/ 4+ severity or stenosis of either valve), history of uncontrolled cardiac arrhythmias, prior symptomatic or asymptomatic myocardial infarction or angina pectoris requiring anti-anginal medication.
4. Prior anthracycline or Trastuzumab therapy.
5. Inability to give informed consent for any reason.